Dashboard
High Management Efficiency with a high ROCE of 33.55%
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.74
Healthy long term growth as Net Sales has grown by an annual rate of 18.34%
With a growth in Net Profit of 105.14%, the company declared Very Positive results in Jun 25
With ROCE of 38.63%, it has a expensive valuation with a 14.99 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
USD 699,433 Million (Large Cap)
47.00
NA
0.00%
1.99
93.61%
38.28
Total Returns (Price + Dividend) 
Eli Lilly & Co. for the last several years.
Risk Adjusted Returns v/s 
News
Eli Lilly & Co. Reports Strong Financial Performance in Latest Quarter
Eli Lilly & Co. has demonstrated impressive financial results for the quarter ending June 2025, showcasing a robust operational performance that has caught the attention of investors. The company, recognized as a large-cap entity, has reported significant increases across various financial metrics, indicating a strong position in the market.
One of the standout figures from the report is the operating cash flow, which reached an all-time high of USD 10,938.2 MM. This substantial cash flow underscores the company's ability to generate liquidity and manage its operations effectively.
Additionally, the return on capital employed (ROCE) for the first half of the year was recorded at an impressive 86.7%, reflecting the efficiency with which the company utilizes its capital to generate profits. This high ROCE is a positive indicator for potential investors looking for companies...
Read MoreIs Eli Lilly & Co. technically bullish or bearish?
As of 31 October 2025, the technical trend for Eli Lilly & Co. has changed from mildly bearish to mildly bullish. The weekly MACD and Bollinger Bands are bullish, while the monthly MACD is mildly bearish. The daily moving averages indicate a mildly bearish stance. Dow Theory shows a mildly bullish trend in both weekly and monthly perspectives. Eli Lilly has outperformed the S&P 500 across multiple periods, with a 1-week return of 9.73% compared to 0.71% for the S&P 500, and a 3-year return of 150.74% versus 76.66%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands....
Read MoreIs Eli Lilly & Co. technically bullish or bearish?
As of 31 October 2025, the technical trend for Eli Lilly & Co. changed from mildly bearish to mildly bullish. The weekly MACD is bullish, supported by bullish Bollinger Bands and a mildly bullish stance in Dow Theory. However, the monthly MACD and KST remain mildly bearish, indicating some caution. The daily moving averages are mildly bearish, and the weekly OBV is mildly bearish while the monthly OBV is bullish. Overall, the mixed signals suggest a mildly bullish stance, but with some underlying bearish indicators that could limit strength. Multi-period return data is not available for comparison with the S&P 500....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 280 Schemes (29.65%)
Held by 763 Foreign Institutions (13.43%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 22.23% vs -5.94% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 105.14% vs -37.43% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 32.00% vs 19.56% in Dec 2023
YoY Growth in year ended Dec 2024 is 102.08% vs -16.08% in Dec 2023






